We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
The characteristics, diagnosis, management and epidemiology of necrotising fasciitis (NF).
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Protocol, questionnaire and quarterly return form for the enhanced surveillance of post-herpetic neuralgia (PHN), a complication of shingles.
Explains how commissioners and health professionals can use data and analysis for decisions about neurology services and interventions.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
Advice for medical professionals to follow when assessing drivers with neurological disorders.
Volume 35 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
You must tell DVLA if you have peripheral neuropathy - download the correct form to let them know
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 January 2024) approved the medicine momelotinib (Omjjara) to treat the symptoms experienced by adult myelofibrosis patients who have moderate or severe anaemia (a low number of red blood cells...
Find out about the symptoms of COVID-19, what to do if you or your child has them and when to get medical help.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).